Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Devonian Health Group's Sloan Ratio for the quarter that ended in Jul. 2024 was 0.00%.
As of Jul. 2024, Devonian Health Group has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Devonian Health Group Sloan Ratio % Historical Data
The historical data trend for Devonian Health Group's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Devonian Health Group's Sloan Ratio %
For the Biotechnology subindustry, Devonian Health Group's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Sloan Ratio % falls into.
Devonian Health Group Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Devonian Health Group's Sloan Ratio for the fiscal year that ended in Jul. 2024 is calculated as
Devonian Health Group's Net Income for the trailing twelve months (TTM) ended in Jul. 2024 was -0.527 (Oct. 2023 ) + -0.901 (Jan. 2024 ) + -0.274 (Apr. 2024 ) + 0.788 (Jul. 2024 ) = $-0.91 Mil.
Devonian Health Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jul. 2024 was -0.443 (Oct. 2023 ) + -0.257 (Jan. 2024 ) + 0.189 (Apr. 2024 ) + 4.614 (Jul. 2024 ) = $4.10 Mil.
Devonian Health Group's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jul. 2024 was 0 (Oct. 2023 ) + 0 (Jan. 2024 ) + 0 (Apr. 2024 ) + 0 (Jul. 2024 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (OTCPK:DVHGF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jul. 2024, Devonian Health Group has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Devonian Health Group Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Devonian Health Group's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DVHGF has been successfully added to your 